Literature DB >> 31604333

Preoperative tumor-associated epilepsy in patients with supratentorial meningioma: factors influencing seizure outcome after meningioma surgery.

Matthias Schneider1, Ági Güresir1, Valeri Borger1, Motaz Hamed1, Attila Rácz2, Hartmut Vatter1, Erdem Güresir1, Patrick Schuss1.   

Abstract

OBJECTIVE: Both pre- and postoperative seizures comprise common side effects that negatively impact patient quality of life in those suffering from intracranial meningioma. Therefore, seizure freedom represents an important outcome measure in meningioma surgery. In the current study the authors analyzed their institutional database to identify risk factors for postoperative seizure occurrence after surgical meningioma therapy in patients with preoperative symptomatic epilepsy.
METHODS: Between February 2009 and April 2017, 187 patients with preoperative seizures underwent resection of supratentorial meningioma at the authors' institution. Seizure outcome was assessed retrospectively 12 months after tumor resection according to the International League Against Epilepsy (ILAE) classification and stratified into favorable (ILAE class I) versus unfavorable (ILAE classes II-VI). A univariate and multivariate analysis was performed to identify factors influencing seizure outcome.
RESULTS: Overall 169 (90%) of 187 patients with preoperative seizures achieved favorable outcome in terms of seizure freedom after meningioma resection. Multivariate analysis revealed peritumoral edema > 1 cm in maximal diameter and WHO grade II and III tumors, as well as a low extent of resection (Simpson grades III-V) as independent predictors for postoperative unfavorable seizure outcome.
CONCLUSIONS: Surgery is highly effective in the treatment of seizures as common side effects of supratentorial meningioma. Furthermore, the present study identified several significant and independent risk factors for postoperative seizure occurrence, enabling one to select for high-risk patients that require special attention in clinical and surgical management.

Entities:  

Keywords:  ILAE = International League Against Epilepsy; KPS = Karnofsky Performance Scale; epilepsy; oncology; postoperative; preoperative; seizure outcome; supratentorial meningioma

Year:  2019        PMID: 31604333     DOI: 10.3171/2019.7.JNS19455

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System.

Authors:  Peter Baumgarten; Mana Sarlak; Daniel Monden; Andrea Spyrantis; Simon Bernatz; Florian Gessler; Daniel Dubinski; Elke Hattingen; Gerhard Marquardt; Adam Strzelczyk; Felix Rosenow; Patrick N Harter; Volker Seifert; Thomas M Freiman
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

2.  Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: Analysis of Surgery-related Risks.

Authors:  Soichi Oya; Fusao Ikawa; Nao Ichihara; Masahiko Wanibuchi; Yukinori Akiyama; Hirofumi Nakatomi; Nobuhiro Mikuni; Yoshitaka Narita
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-12-23       Impact factor: 1.742

3.  Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection.

Authors:  Matthias Schneider; Patrick Schuss; Valeri Borger; Motaz Hamed; Inja Ilic; Anna-Laura Potthoff; Attila Racz; Niklas Schäfer; Erdem Güresir; Rainer Surges; Ulrich Herrlinger; Hartmut Vatter
Journal:  J Neurooncol       Date:  2021-02-07       Impact factor: 4.130

4.  Early postoperative seizures (EPS) in patients undergoing brain tumour surgery.

Authors:  Tunc Faik Ersoy; Sami Ridwan; Alexander Grote; Roland Coras; Matthias Simon
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

Review 5.  Health-related quality of life in meningioma.

Authors:  Sameah Haider; Martin J B Taphoorn; Katharine J Drummond; Tobias Walbert
Journal:  Neurooncol Adv       Date:  2021-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.